Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes

Prevention of Fluid RetentionDiabetes 56:248–255

  • Karalliedde, J.
  • Viberti, G. C.

  • Unit for Metabolic Medicine, Department of Diabetes and Endocrinology, Cardiovascular Division, King's College London School of Medicine, Guy's Hospital, King's College London, London, U.K

Address correspondence to Dr. J. Karalliedde, Unit for Metabolic Medicine, 5th Floor Thomas Guy House, Guy's Hospital, St. Thomas Street, London SE1 9RT. E-mail: [email protected]

Received and accepted for publication 1 February 2007

Diabetes 56(5):p e3, May 2007.
Copyright © 2007 by the American Diabetes Association, Inc.